{
    "2020-02-09": [
        [
            {
                "time": "",
                "original_text": "瑞德西韦三期临床研究开展 两家上市公司参与",
                "features": {
                    "keywords": [
                        "瑞德西韦",
                        "三期临床",
                        "上市公司",
                        "泰格医药",
                        "迪安诊断"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "瑞德西韦三期临床研究开展 泰格医药、迪安诊断参与",
                "features": {
                    "keywords": [
                        "瑞德西韦",
                        "三期临床",
                        "泰格医药",
                        "迪安诊断"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}